drugset / Trial / NCT07337460
Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, single-arm, prospective trial to explore the efficacy and safety of Icaritin Soft Capsules combined with postoperative adjuvant hepatic arterial infusion chemotherapy(HAIC) with Modified Folinic acid, Fluorouracil, and Oxaliplatin (mFOLFOX) in hepatocellular carcinoma (HCC) with high-risk recurrence factors.
Timeline
- Start
- 2025-11-01
- Primary completion
- 2027-11-30
- Completion
- 2028-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Icaritin | Small molecule | 2400 mg | Oral |
| Background | Leucovorin | Small molecule | 400 mg/m2 | Other |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | Other |
| Background | fluorouracil | Small molecule | 400 mg/m2 | Other |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | Other |